TowardPi / 图湃医疗

About TowardPi / 图湃医疗

TowardPi Medical Technology, established in October 2017, is a high-growth company specializing in the development and manufacturing of high-end ophthalmic medical equipment. Headquartered in Beijing's Zhongguancun Life Science Park, the company's core technology originated from scientific and technological achievements at Tsinghua University. The founding technical team is composed of dozens of Tsinghua University teachers, students, and alumni.

The company operates in the global ophthalmology market, providing advanced diagnostic and surgical equipment to clinicians and hospitals. Its business model revolves around the in-house research, development, production, and sale of this equipment. This vertical integration allows for meticulous quality control and the development of proprietary technologies. A significant portion of its revenue is reinvested into research and development, with an annual investment of nearly 100 million yuan. TowardPi has successfully secured substantial funding through multiple rounds, including a 200 million yuan Series D in July 2024 and a ¥500 million ($70M) Series E in March 2025, with plans to pursue an IPO on the STAR Market.

TowardPi offers a comprehensive portfolio of ophthalmic devices. A flagship product is the "BMizar" SS-OCT, which features a scanning speed of 400,000 A-scans per second and provides ultra-wide-field OCT Angiography (OCTA) imaging. Another key product, the "YAlkaid" SS-OCT, operates at 100kHz with a 1060nm wavelength for superior penetration through cataracts and opacities. The company also produces the "Zalioth" optical biometer, surgical microscopes like "Baryon" and "Focean," and the "Zursa" ultra-widefield fundus camera. These products are designed to provide detailed imaging and precise measurements of both the anterior and posterior segments of the eye, aiding in the diagnosis and management of various ophthalmic diseases. The company has achieved a significant footprint in its domestic market, ranking first in China's public hospital ophthalmic OCT market in 2023 with a 27% share. It is also expanding globally, with products installed in several European and Latin American countries and a strategic partnership with Nikon Solutions for exclusive distribution in Japan.